A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis (NCT06655155)
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months. More information can be found on: https://clinicaltrials.argenx.com/esscape
Who can join: Review the eligibility criteria below.
Location: Arizona Arthritis and Rheumatology Associates — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (77 Sites)
Showing the first 25 of 77 sites.
- Arizona Arthritis and Rheumatology Associates — Phoenix, Arizona
- UCLA Ronald Reagan University of California Los Angeles Medical Center — Los Angeles, California
- IRIS Research and Development LLC — Plantation, Florida
- University of Illinois Health Outpatient Care Center — Chicago, Illinois
- DelRicht Research, LLC — New Orleans, Louisiana
- Johns Hopkins Asthma and Allergy Center — Baltimore, Maryland
- Thomas Jefferson University — Columbia, Maryland
- University of Michigan Hospital — Ann Arbor, Michigan
- Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Aprillus Asistencia e Investigacion — Buenos Aires,
- Instituto de Investigación Clínica TyT — Buenos Aires,
- Consultorios Médicos Dr. Doreski - Fundacion Respirar — Buenos Aires,
- Hospital General de Agudos Dr. José María Ramos Mejia — Buenos Aires,
- Sanatorio Allende S.A. — Córdoba,
- Centro de Investigaciones Reumatológicas — San Miguel de Tucumán,
- Clínica Mayo de U.M.C.B. S.R.L — San Miguel de Tucumán,
- Centro de Investigaciones Médicas Tucumán — San Miguel de Tucumán,
- UZ Gent — Ghent,
- UZ Brussel — Jette,
- Medical Center Artmed OOD — Plovdiv,
- Diagnostic Consultative Center Convex EOOD — Sofia,
- BIOCINETIC Ltda — Santiago,
- Centro de Investigaciones Clinicas UC (CICUC) — Santiago,
- Centro de especialidades médicas Vanguardia — Temuco,
- Clinical Hospital Centre Osijek — Osijek,
📞 Contact the Study Coordinator
Phone: (857) 350-4834
Email: clinicaltrials@argenx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Sclerosis (SSc)
- Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) — La Jolla, California
- Mycophenolate After Stem Cell Transplant for Systemic Sclerosis — Ottawa, Ontario
- Intralesional Injection of STS in Treatment of Calcinosis — Pittsburgh, Pennsylvania
- Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images — New Haven, Connecticut
- Systemic Sclerosis DIet for GastrointESTinal Symptoms — Ann Arbor, Michigan
Explore by condition: All Systemic Sclerosis (SSc) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.